DMAA — Drugs Made In America Acquisition Cashflow Statement
0.000.00%
Last trade - 00:00- $314.45m
- $314.45m
- 13
- 46
- 35
- 20
Annual cashflow statement for Drugs Made In America Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | ARS | 10-K |
| Standards: | — | USG |
| Status: | Final | Final |
| Net Income/Starting Line | 0 | -0.28 |
| Non-Cash Items | — | 0.03 |
| Other Non-Cash Items | ||
| Changes in Working Capital | — | 0.077 |
| Change in Accrued Expenses | ||
| Cash from Operating Activities | 0 | -0.172 |
| Financing Cash Flow Items | — | -0.364 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | — | 0.174 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 0 | 0.001 |